TGI-15 is a highly selective prostaglandin F receptor antagonist. TGI-15 inhibits downstream signaling pathways by blocking the binding of PGF2 α to FP receptors. TGI-15 can be used for research on fibrotic and inflammatory conditions.

AGN192093 is a TP agonist (EC50 = 1.3 nM). AGN192093 exhibits potent and selective thromboxane analog activity in rat blood vessels.

LCB 2853 (sodium) is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 (sodium) exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 (sodium) can be used for the research of cardiovascular disease, such as hypertension.

AM-461 is a DP2 receptor (Prostaglandin Receptor) antagonist. AM-461 can be used for the researches of inflammation and immunology, such as asthma.

T26A is a competitive prostaglandin transporter (PGT) inhibitor (Ki=378 nM). T26A is promising for research of prostaglandin signaling and inflammatory diseases (e.g., glaucoma, pulmonary hypertension) .

GR63799 (GR-63799X) is a selective EP3 receptor agonist. GR63799 induces bladder overactivity. GR63799 can be used for the study of the pathophysiological mechanism of overactive bladder (OAB).

RJG-2036 is a potent covalent inhibitor of human prostaglandin reductase 2 (PTGR2)(IC50=100 nM). RJG-2036 inhibits NADPH-dependent reduction, significantly reducing secretion of proinflammatory cytokines like TNF-α and multiple eicosanoids in LPS-stimulated THP-1 macrophages. RJG-2036 is promising for research of inflammatory diseases.

CCI17464 is a selective, orally active EP4 agonist. CCI17464 can be used in a Freund's complete adjuvant (FCA) acute rat inflammatory pain model and shows complete reversal of allergic reactions.

RS 93427-007 is an orally active prostacyclin stable mimetic agent. RS 93427-007 can be used for the research of cardiovascular disease, such as atherosclerosis.

Imitrodast sodium is an inhibitor of thromboxane synthase. Imitrodast sodium can be used in the research of bronchoconstriction.

Y-20811 (sodium) is a selective and orally active thromboxane synthetase inhibitor. Y-20811 (sodium) can irreversibly inhibit thromboxane (TX) A2 synthesis. Y-20811 (sodium) can be used for the research of cardiovascular disease, such as thrombosis.

KC-764 is an orally active, reversible cyclooxygenase inhibitor with relative selectivity for platelet cyclooxygenase. KC-764 inhibits platelet thromboxane A2 (TXA2) production and platelet aggregation, with IC50s of 0.23 μM and 26 nM, respectively. KC-764 can be used for the research on antiplatelet and recurrence prevention in ischemic stroke.

Naxaprostene is a prostacyclin analogue. Naxaprostene was much more selective for IP receptors and tended towards partial agonism. Naxaprostene inhibits ADP-induced platelet aggregation. It has been shown to prevent rabbit carotid artery thrombosis.

AR-102 isopropyl ester is a second-generation prostaglandin FP agonist. AR-102 isopropyl ester can be studied in research for glaucoma and ocular hypertension.

CGS 22652 is a potent thromboxane A2 receptor antagonist. CGS 22652 has selective thromboxane A2 synthase inhibitory properties. CGS 22652 can be used in the research of coronary artery thrombosis.

SC-42867 is a PGE2 antagonist. SC-42867 can be metabolized in the liver through oxidative N-dealkylation, aromatic hydroxylation, and binding reactions. SC-42867 can be used for research on metabolic conditions.

U-46619 Glycine methyl ester has a modification at the C-1 position of U-46619, which uniquely alter its binding properties to the TP receptor or any of the PGH2-metabolizing enzymes. U-46619 is a stable analog of the endoperoxide PGH2. U-46619 is also an agonist of TP receptor. U-46619 can change the shape of platelet, aggregation and contraction of vascular smooth muscle. U-46619 Glycine methyl ester can be studied in research to explore the inhibition of various enzymes in the arachidonic acid metabolic pathway. U-46619 Glycine methyl ester can also act as a lipophilic prodrug form of U-46619 that alters its distribution and pharmacokinetic properties.

Carbaprostacyclin-biotin (cPGI-biotin; Carbacyclin-biotin) is a biotin-bound Carbacyclin (Carbaprostacyclin)). Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

U-46619 serinol amide is a derivative of U-46619. U-46619 serinol amide is a stable analog of Thromboxane A2 (TXA2). U-46619 serinol amide is a potent TXA2 agonist that can induce platelet shape change and aggregation.

U-44069 serinol amide is a derivative of U-44069. U-44069 serinol amide is a stable analog of the endoperoxide prostaglandin H2. U-44069 serinol amide is a vasoconstrictor that can induce preglomerular Ca2+ influx.

tetranor-Prostaglandin E1 is metabolite of Prostaglandin E1 and Prostaglandin E2 that is formed by β-oxidation.

tetranor-PGFM is the major urinary metabolite of Dinoprost, acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM.

Taprostene sodium is a partial agonist at prostanoid prostacyclin (IP) receptors. Taprostene sodium interacts additively with Prostaglandin E2 (PGE2).

Prostaglandin K1 (compound 46) is a structurally modified analog of prostacyclin (prostanoid) with an EC50 of 2800 nM for EP1 and a Ki of 2800 nM.

Prostaglandin E1 isopropyl ester is an isopropyl ester form of prostaglandin E1. Prostaglandin E1 isopropyl ester exhibits a faster penetration flux than prostaglandin E1.

PGF2α analogue-1 is an analog of Dinoprost. Z-CITCO is an agonist of constitutive androstane receptor (CAR) with an EC50 value of 3.9 µM.

ONO-AE3-208 (sodium salt) is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 (sodium salt) shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 (sodium salt) suppresses cell invasion, migration, and metastasis of prostate cancer.

O-Acetylsalicylhydroxamic acid is an acetylation inhibitor of prostaglandin H2 synthase that can suppress PGE2 synthesis in the body and block the cyclooxygenase activity of PGHS in vitro. O-Acetylsalicylhydroxamic acid requires the presence of the active site residue Ser-529 to act on human PGHS-1; the S529A mutant is resistant to the inactivation effects of this inhibitor.

MED 27 is an inhibitor of thromboxane synthase and thromboxane A2 receptors. MED 27 can inhibit rat platelet aggregation at doses much lower than that of acetylsalicylic acid.

Latanoprost amide is a derivative of the F-prostaglandin (FP) receptor agonist Latanoprost.